Current Assets
Derivative assets
Pfizer Derivative assets increased by 23.9% to $659M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.7%, from $842M to $659M. Over 5 years (FY 2020 to FY 2025), Derivative assets shows an upward trend with a 7.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
Metric ID:
fin_derivative_assetsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $455M | $720M | $968M | $1.1B | $1.89B | $2.77B | $1.08B | $1.03B | $853M | $1.13B | $700M | $781M | $795M | $633M | $1.52B | $842M | $367M | $418M | $532M | $659M |
| QoQ Change | — | +58.2% | +34.4% | +14.0% | +71.5% | +46.4% | -61.1% | -4.5% | -17.1% | +32.1% | -37.9% | +11.6% | +1.8% | -20.4% | +139.5% | -44.5% | -56.4% | +13.9% | +27.3% | +23.9% |
| YoY Change | — | — | — | — | +316.0% | +284.9% | +11.4% | -6.8% | -54.9% | -59.3% | -35.1% | -24.1% | -6.8% | -43.8% | +116.6% | +7.8% | -53.8% | -34.0% | -64.9% | -21.7% |
Range$367M – $2.77B
CAGR+8.1%
Avg YoY Growth+20.7%
Median YoY Growth-22.9%
Current Streak3 quarters growth
Derivative assets at Other Companies
Frequently Asked Questions
- What is Pfizer's derivative assets?
- Pfizer (PFE) reported derivative assets of $659M in Q1 2026.
- How has Pfizer's derivative assets changed year-over-year?
- Pfizer's derivative assets decreased by 21.7% year-over-year, from $842M to $659M.
- What is the long-term trend for Pfizer's derivative assets?
- Over 5 years (2020 to 2025), Pfizer's derivative assets has grown at a 7.4% compound annual growth rate (CAGR), from $373M to $532M.